Comparison
CJC-1295 vs. Epitalon
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Research other
CAS no.
no data
307297-39-8
Molecular weight
3647.3 g/mol
390.35 g/mol
Half-life
144 h
0.3 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACAla-Glu-Asp-GlyMechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Epitalon
Postulated mechanisms include modulation of gene expression in pinealocytes, telomerase activation (observed in cell culture studies) and influence on melatonin synthesis. A defined primary receptor is not established; the mechanistic basis rests on in-vitro and animal data from the Khavinson group.
Evidence base
Highest evidence
Human trial
Human trial
Studies
3
4
of which in humans
2
1
Effects recorded
3
4
Open conflicts
1
1
Documented adverse events
3
1